Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.

[1]  R. Yaeger,et al.  434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC) , 2021, Annals of Oncology.

[2]  R. Govindan,et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.

[3]  J. Shen,et al.  Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer , 2021, JCO precision oncology.

[4]  J. Desai,et al.  KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. , 2020, The New England journal of medicine.

[5]  N. Rosen,et al.  EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. , 2020, Cancer discovery.

[6]  M. Fassan,et al.  KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. , 2020, Clinical colorectal cancer.

[7]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[8]  Alex Y. Ge,et al.  KRASG12C inhibition produces a driver-limited state revealing collateral dependencies , 2019, Science Signaling.

[9]  Tae Won Kim,et al.  Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Mountford,et al.  Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer , 2017, British Journal of Cancer.

[11]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[12]  V. Heinemann,et al.  Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Frank McCormick,et al.  K-Ras protein as a drug target , 2016, Journal of Molecular Medicine.

[14]  C. Atreya,et al.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Ying Cheng,et al.  Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2015, The Lancet. Oncology.

[16]  Marc Peeters,et al.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer. , 2015, The New England journal of medicine.

[17]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[18]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[19]  N. Sugimoto,et al.  TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2012, The Lancet. Oncology.

[20]  J. Neumann,et al.  Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. , 2009, Pathology, research and practice.

[21]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[22]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J Jack Lee,et al.  A predictive probability design for phase II cancer clinical trials , 2008, Clinical trials.